The Union Health Ministry has said that license has been given to five more manufacturers for Amphotericin-B production, used in the treatment of black fungus, and they will start producing 1,11,000 vials of the drug per month from July.
Several states and union territories have reported an increasing number of patients suffering from COVID complications in recent days. Amphotericin-B is an antifungal drug used to treat a fungal infection called mucormycosis, or “black fungus”.
The fungal infection seems to be more prevalent among the COVID patients of late. So the government of India has decided to boost up the production of the drug. As the spread of black fungus spreads across the country, the central government has taken steps to increase the production of the drug which is used for treating the disease.
The disease is endemic in Delhi, Uttar Pradesh, Telangana, Rajasthan, Maharashtra, Tamil Nadu and Pondicherry. Apart from the existing six manufacturers, an additional five pharma companies have been granted licenses.
The five manufacturers which have been given the license to produce the Amphotericin-B within the country are NATCO Pharmaceuticals, Hyderabad, Alembic Pharmaceuticals, Vadodara, Gufic Biosciences Ltd, Gujarat, Emcure Pharmaceuticals, Pune and Lyka in Gujarat.